Ipsen chief executive David Meek has resigned from the Paris-based pharmaceutical company to join FerGene as its CEO. Cambridge, MA-based FerGene was formed in November by Ferring Pharmaceuticals and Blackstone Life Sciences, which pumped a combined $570 million into the new business. Operating as a subsidiary of Ferring, FerGene will handle US commercialization of nadofaragene … Continue reading “Ipsen’s Meek Departs for CEO Role at Gene Therapy NewCo FerGene”
Nimbus Therapeutics Taps Annie Chen to Lead Subsidiary
Nimbus Therapeutics has named Annie Chen to the role of president at its subsidiary, Nimbus Lakshmi. Chen is currently chief medical officer of Cambridge, MA-based Nimbus Therapeutics, and she will continue serving in that role. The company uses software to discover and design new drugs, some of which are developed by its subsidiaries. Nimbus Lakshmi … Continue reading “Nimbus Therapeutics Taps Annie Chen to Lead Subsidiary”
Palo Alto Health Names Dean Sawyer President & CEO
Dean Sawyer has joined Palo Alto Health Sciences as its president and CEO. He comes to the Kirkland, WA-based company from Rx-Precision, where he was CEO. Sawyer’s experience also includes positions at Sentrian and Frost Data Capital. Palo Alto Health markets Freespira, a digital therapeutic that has FDA clearance for treating symptoms of panic disorder, … Continue reading “Palo Alto Health Names Dean Sawyer President & CEO”
ALS Fund Talks Investments and Strategy as it Kicks Off $100M Campaign
The ALS Investment Fund has teamed with the ALS Association and is looking to establish new partnerships as part of its efforts to raise $100 million and collate a diversified set of portfolio companies. Craig Boyce, managing partner of the ALS Investment Fund, tells Xconomy it would have been crazy to start the fund 25 … Continue reading “ALS Fund Talks Investments and Strategy as it Kicks Off $100M Campaign”
Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s
Huntington’s disease drug research has focused mainly on the genetic roots of the rare neurodegenerative disorder. Triplet Therapeutics is taking a different tack by targeting a DNA repair mechanism gone awry, an approach that CEO Nessan Bermingham says could offer a better way to treat that disease and potentially dozens of others. Cambridge, MA-based Triplet … Continue reading “Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s”
Organovo’s Demise Offers Path for Tarveda to Join the Public Markets
Organovo raised millions of dollars from investors to fuel its goal of developing 3D “bioprinted” human tissues for use in people with end-stage liver disease and other life-threatening illnesses. But the San Diego company fell short of bringing its lead regenerative medicine program into clinical trials, and now it is charting a course as a … Continue reading “Organovo’s Demise Offers Path for Tarveda to Join the Public Markets”
Zentalis Pharma Names Melissa Epperly as Its Chief Financial Officer
Zentalis Pharmaceuticals, which is developing small molecule drugs for cancer, appointed Melissa Epperly as its chief financial officer. Epperly was most recently CFO at clinical-stage gene therapy developer Psioxus Therapeutics; previously she was CFO and head of business development at R-Pharm US, a commercial-stage oncology pharmaceutical company. Her prior experience includes time as a director … Continue reading “Zentalis Pharma Names Melissa Epperly as Its Chief Financial Officer”
Grail Appoints Illumina’s Gautam Kollu as Chief Commercial Officer
Grail, the Illumina (NASDAQ: [[ticker:ILMN]]) spinout that has raised more than $1.5 billion to advance its development of a blood test for early detection of cancer, has appointed Gautam Kollu as its chief commercial officer. Kollu joins the company from its parent firm, where he was vice president of global market development. His prior experience … Continue reading “Grail Appoints Illumina’s Gautam Kollu as Chief Commercial Officer”
Wave Stock Crashes After Decision to Halt Duchenne Drug Studies
Wave Life Sciences saw its stock price plunge nearly 60 percent Monday following the company’s decision to discontinue development of its investigational Duchenne muscular dystrophy drug, suvodirsen, after an interim analysis from a Phase 1 study. Cambridge, MA-based Wave (NASDAQ: [[ticker:WVE]]) was testing suvodirsen as a potential treatment for Duchenne, a genetic neuromuscular disorder that … Continue reading “Wave Stock Crashes After Decision to Halt Duchenne Drug Studies”
Cell Reprogramming Startup Bit Bio Inks Pact With Charles River
Charles River Laboratories International is making moves in the cell therapy space after signing on the cell reprogramming startup Bit Bio and announcing plans to acquire a biomaterials company for $380 million. The Wilmington, MA-based contract research organization (CRO) last week announced that it has entered into an exclusive discovery and safety services partnership with … Continue reading “Cell Reprogramming Startup Bit Bio Inks Pact With Charles River”
Axsome’s Depression Drug Meets Phase 3 Goals, FDA Filing Planned
An experimental Axsome Therapeutics drug has succeeded in improving depression symptoms in a late-stage study, and the company is now preparing to seek regulatory approval next year. Axsome (NASDAQ: [[ticker:AXSM]]) is testing its drug, AXS-05, as a treatment for major depressive disorder (MDD). The Phase 3 study enrolled 327 patients with moderate-to-severe major depressive disorder. … Continue reading “Axsome’s Depression Drug Meets Phase 3 Goals, FDA Filing Planned”
Building a Better 3D Bioprinter: GE Healthcare and ASLS Combine Tech
GE Healthcare Life Sciences and ASLS have teamed up to offer a new platform that can design, build, and image living 3D tissue models for drug discovery and development. ASLS, Advanced Solutions Life Sciences, is a subsidiary of Advanced Solutions headquartered in Louisville, KY. Its patented Angiomics technology enables users to create 3D tissue models … Continue reading “Building a Better 3D Bioprinter: GE Healthcare and ASLS Combine Tech”
Amarin’s Fish-Oil Pill Wins FDA Nod to Cut Heart Attack, Stroke Risk
A prescription pill derived from fish-oil received the regulatory nod Friday to expand its use as a supplementary treatment, alongside statins, to more patients at risk of heart attack or stroke. The FDA approved the Amarin Pharma drug, icosapent ethyl (Vascepa), for use as a secondary treatment for adults who are taking statins and have elevated … Continue reading “Amarin’s Fish-Oil Pill Wins FDA Nod to Cut Heart Attack, Stroke Risk”
miRagen Promotes Diana Escolar to Chief Medical Officer
Diana Escolar has been appointed chief medical officer of miRagen Therapeutics (NASDAQ: [[ticker:MGEN]]). Escolar joined the Boulder, CO, biotech in 2018 as senior vice president of clinical sciences. She will be taking on the duties of Paul Rubin, miRagen’s executive vice president of R&D. The company says Rubin will leave at the end of this … Continue reading “miRagen Promotes Diana Escolar to Chief Medical Officer”
Alector Appoints Suliman President & Chief Operating Officer
Shehnaaz Suliman has been appointed president and chief operating officer of Alector (NASDAQ: [[ticker:ALEC]]). She joins the South San Francisco biotech from Theravance Biopharma, where she was senior vice president of corporate development and strategy. Her experience also includes positions at Genentech, Roche Partnering, and Gilead Sciences (NASDAQ: [[ticker:GILD]]). Alector is developing drugs that target … Continue reading “Alector Appoints Suliman President & Chief Operating Officer”
Pyxis Oncology Names Sullivan CEO, Steinberg Remains on the Board
Pyxis Oncology has appointed Lara Sullivan to serve as its CEO. She is also joining the Boston company’s board of directors. Sullivan succeeds David Steinberg, Pyxis’s founding CEO and a general partner at Longwood Fund. Steinberg will remain on the company’s board as an independent director. Sullivan was most recently founder and president of Pfizer … Continue reading “Pyxis Oncology Names Sullivan CEO, Steinberg Remains on the Board”
Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More
If you’re keeping track, FDA drug approvals have been on a tear in the past month with several decisions coming well ahead of their targeted dates. And then there’s Sarepta Therapeutics. Late Thursday, the FDA announced approval of the Cambridge, MA, biotech’s drug for Duchenne muscular dystrophy in patients who have a specific mutation. The … Continue reading “Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More”
In an About-Face, FDA Approves Second Sarepta Muscular Dystrophy Drug
Sarepta Therapeutics received an early holiday gift Thursday—approval of golodirsen (Vyondys 53), its second Duchenne muscular dystrophy treatment, which the FDA rejected in August. The agency had dinged the application over potential side effects, namely a risk of infections from the “ports” used to infuse the drug, and kidney problems observed in animals in which … Continue reading “In an About-Face, FDA Approves Second Sarepta Muscular Dystrophy Drug”
miRagen Restructures to Focus on Fibrosis, Inks $20M Stock Deal
MicroRNA therapies developer miRagen Therapeutics is scaling back work on its most advanced cancer drug candidate and shifting resources to a compound being developed to treat fibrosis in the lungs. The pipeline shuffle will be accompanied by a corporate shakeup. Boulder, CO-based miRagen (NASDAQ: [[ticker:MGEN]]) is also laying off some of its staff. The company … Continue reading “miRagen Restructures to Focus on Fibrosis, Inks $20M Stock Deal”
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
An osteoporosis drug developed by Amgen now has marketing approval in Europe, but it carries a warning that the medicine can raise the risk of cardiovascular problems. Romosozumab (Evenity) treats postmenopausal woman who have osteoporosis, a disease that weakens bones, making them susceptible to fracture. The antibody drug, given as a monthly injection, was developed … Continue reading “Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning”
Aspen Neuro Bags $6.5M to Test Parkinson’s Disease Stem Cell Therapy
Nearly nine years ago Jeanne Loring and her colleagues at Scripps Research debuted a test that leveraged advances in genomics and data science to determine, without testing in animals, whether human stem cells were “pluripotent,” or able to become any type of cell in the body. Being able to prove that has become increasingly important … Continue reading “Aspen Neuro Bags $6.5M to Test Parkinson’s Disease Stem Cell Therapy”
Prometheus Bio Taps Thierry Dervieux as Chief Development Officer
Prometheus Biosciences on Tuesday said it has appointed Thierry Dervieux as chief development officer, diagnostics, and medical laboratory director. The San Diego-based biotech, created this summer through the acquisition of Prometheus Laboratories by Precision IBD, is working to create new drugs and companion diagnostics for people with gastroenterology disorders and autoimmune diseases. Dervieux was most … Continue reading “Prometheus Bio Taps Thierry Dervieux as Chief Development Officer”
Locana Names Casebia Therapeutics’s Jim Burns as New CEO
Locana said Tuesday that it has appointed Jim Burns, most recently CEO of Casebia Therapeutics, as its new chief executive. Burns ran Casebia, a joint venture between CRISPR Therapeutics (NASDAQ: [[ticker:CRSP]]) and Bayer, for three years. Previously he spent three decades at Sanofi Genzyme. He succeeds Jeffrey Ostrove, who was named to the top role … Continue reading “Locana Names Casebia Therapeutics’s Jim Burns as New CEO”
Iterum’s Antibiotic for Super Bugs Falls Short in Phase 3, Shares Sink
Iterum Therapeutics’ bid to bring patients a new antibiotic that’s safer than currently available drugs has fallen short of the main efficacy goal of a late-stage clinical trial. But the company is pinning its hopes on another Phase 3 study that will report data early next year. Iterum (NASDAQ: [[ticker:ITRM]]) reported preliminary Phase 3 data … Continue reading “Iterum’s Antibiotic for Super Bugs Falls Short in Phase 3, Shares Sink”
Flagship’s Cellarity Aims to Advance Cell Behavior-Based Therapeutics
The latest startup to emerge from Flagship Pioneering aims to change drug discovery by starting the process with a clear understanding of cell behavior. Cellarity—like many other startups looking to revamp the slow, costly process of developing new medicines—is using machine-learning tools to do so, leveraging computational advances to advance a new way of thinking … Continue reading “Flagship’s Cellarity Aims to Advance Cell Behavior-Based Therapeutics”
Flexion Co-Founder, Chief Scientific Officer Neil Bodick to Retire
Neil Bodick, chief scientific officer of Flexion Therapeutics (NASDAQ: [[ticker:FLXN]]), will retire on Jan. 3. After co-founding the company in 2007, Bodick served as its chief medical officer. He became chief scientific officer in 2017 following FDA approval of the company’s extended-release formulation of triamcinolone acetonide (Zilretta), a treatment for knee pain. After retiring, Flexion … Continue reading “Flexion Co-Founder, Chief Scientific Officer Neil Bodick to Retire”
Replimune Taps Ex-Merrimack Exec for Chief Financial Officer Post
Replimune Group (NASDAQ: [[ticker:REPL]]) has appointed Jean Franchi to serve as chief financial officer, the same position she held most recently at Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]). Franchi’s experience also includes positions at Genzyme, Dimension Therapeutics, and Good Start Genetics. Woburn, MA-based Replimune is developing oncolytic immune-gene therapies to treat cancer.
KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test
A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista (NASDAQ: [[ticker:KALV]]) developed its drug, KVD001, to treat diabetic macular edema (DME), a complication of diabetes that can lead to blindness. On Monday, Cambridge, MA-based KalVista said patients treated with the drug, given as … Continue reading “KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test”
Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules
Zentalis Pharmaceuticals is banking on small molecules for cancer—leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the science speak for itself. Since it was founded five years ago, the company has moved three compounds into the clinic. How? By operating under the radar. “If you … Continue reading “Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules”
Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer
The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other kinds of disease. Scripps’s early-stage drug discovery division, Calibr, last year inked a big partnership with North Chicago, IL-based AbbVie (NYSE: [[ticker:ABBV]]) to develop potential treatments for solid cancer … Continue reading “Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer”
Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs
Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at the earliest stages with a new $210 million venture capital fund. The Perceptive Xontogeny Venture Fund (PXV) is led by Chris Garabedian (pictured above, center), a … Continue reading “Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs”
Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego’s Synthorx
Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions. Now French biopharma Sanofi has struck a deal to add the startup to its oncology business in a transaction that values the company at about $2.5 billion. The move is … Continue reading “Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego’s Synthorx”
Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals
Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3 study. Aurinia Pharmaceuticals (NASDAQ: [[ticker:AUPH]]) is testing its drug, voclosporin, as a treatment for lupus nephritis (LN), which can occur when lupus, an autoimmune disorder, causes the immune system … Continue reading “Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals”
Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule
Merck is acquiring cancer drug developer ArQule for $2.7 billion, a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug from AbbVie. According to terms of the agreement announced Monday, a Merck (NYSE: [[ticker:MRK]]) subsidiary will pay $20 for each share of ArQule (NASDAQ: [[ticker:ARQL]]), a 107 percent … Continue reading “Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule”
BridgeBio Pharma Onboards Eli Wallace to Lead Oncology Programs
Palo Alto, CA-based BridgeBio Pharma (NASDAQ: [[ticker:BBIO]]) has named Eli Wallace as its chief scientific officer in residence for oncology. In this role, Wallace will oversee the company’s current drug discovery projects, while helping identify and develop new oncology programs. Wallace has more than two decades of experience and was most recently the chief scientific … Continue reading “BridgeBio Pharma Onboards Eli Wallace to Lead Oncology Programs”
Insitro Hires Serafim Batzoglou As Its First Chief Data Officer
The San Francisco-based drug discovery startup, Insitro, has hired its first chief data officer. Serafim Batzoglou joins the company from Illumina (NASDAQ: [[ticker:ILMN]]), out of San Diego, where he was the vice president of applied and computational biology. He also was a professor of computer science at Stanford University and co-founded the genomics analytics startup, … Continue reading “Insitro Hires Serafim Batzoglou As Its First Chief Data Officer”
AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets
After joining AstraZeneca’s Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and cardiovascular diseases. Under the collaboration, expected to last multiple years, Gatehouse will use its sRNAlytics platform to identify small RNA (sRNA) signatures, which the company says help in … Continue reading “AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets”
3 Takeaways From the Resurrection of Biogen’s Alzheimer’s Drug
The name of the experimental drug was heard so frequently in hotel hallways at the conference that it sounded like an incantation: aducanumab, aducanumab, aducanumab. Regardless of the eventual FDA verdict on Biogen’s once-bagged, now-revived anti-amyloid antibody, data from clinical trials of the treatment have inarguably altered the course of drug discovery and development for … Continue reading “3 Takeaways From the Resurrection of Biogen’s Alzheimer’s Drug”
Duke’s Jacob Jacobsen Joins Evecxia as Chief Scientific Officer
Evecxia co-founder Jacob Jacobsen has been appointed to serve as the biotech’s chief scientific officer. Jacobsen was most recently a scientist in the Duke University lab of Marc Caron, another co-founder of Research Triangle Park, NC-based Evecxia. His industry experience includes positions at Lundbeck and NeuroSearch. Evecxia’s lead therapeutic candidate, EVX-101, is in development as … Continue reading “Duke’s Jacob Jacobsen Joins Evecxia as Chief Scientific Officer”
Akcea Therapeutics Appoints Alex Howarth Chief Operating Officer
Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) has named Alex Howarth its new chief operating officer. He was most recently president at Lycera. His experience also includes positions at moksha8, Vitae Pharmaceuticals, and GlaxoSmithKline (NYSE: [[ticker:GSK]]). Howarth joins Boston-based Akcea following a corporate shakeup in September that led to the departure of three executives. The rare disease drug … Continue reading “Akcea Therapeutics Appoints Alex Howarth Chief Operating Officer”
Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis
Acadia Pharmaceuticals revealed late-stage clinical data this week that could support bringing its drug for psychosis to a broader group of patients. The Acadia (NASDAQ: [[ticker:ACAD]]) drug pimavanserin (Nuplazid) is currently approved for treating psychosis associated with Parkinson’s disease. But the San Diego-based company has also been testing the drug in dementia-related psychosis (DRP), which … Continue reading “Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis”
FDA Puts Partial Hold on Tests of Ipsen Drug Acquired in $1B Deal
Two clinical trials testing an Ipsen drug in rare connective tissue disorders have been placed on partial hold after safety concerns about chronic dosing of the compound emerged. The partial hold applies to patients under 14 years of age in Phase 2 and Phase 3 tests of the drug, palovarotene. But the Paris-based company, which … Continue reading “FDA Puts Partial Hold on Tests of Ipsen Drug Acquired in $1B Deal”
Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More
It’s been a roller-coaster year for those hoping for new drugs to treat Alzheimer’s disease, a leading cause of death with rising treatment costs and no clear answer yet as to its cause. Clearing proteins, such as amyloid and tau, was once seen as the top contender for stopping or slowing neurodegeneration. Costly failures forced … Continue reading “Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More”
Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Results
Biogen revealed detailed results from its Alzheimer’s trial to a jam-packed room of eager conference attendees this week—and while some described it as a major advance in the field, others were less convinced. Samantha Budd Haeberlein, Biogen’s vice president of clinical development, took the stage Thursday morning in San Diego at Clinical Trials on Alzheimer’s … Continue reading “Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Results”
FDA Rejects Enzyvant’s Regenerative Therapy for Rare Immune Disorder
[Corrected 12:27 p.m. See below.] The FDA has rejected an experimental regenerative therapy that Enzyvant developed to restore immune system function in babies born with a rare disorder. The agency cited manufacturing issues, according to the company. Enzyvant received the notification, formally known as a complete response letter, on Wednesday, CEO Rachelle Jacques tells Xconomy. … Continue reading “FDA Rejects Enzyvant’s Regenerative Therapy for Rare Immune Disorder”
Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%
An experimental Sage Therapeutics drug intended to alleviate depression symptoms quickly failed to beat a placebo in a pivotal study, the company reported Thursday. Cambridge, MA-based Sage (NASDAQ: [[ticker:SAGE]]) has been testing its drug, SAGE-217, as a treatment for the symptoms of major depressive disorder. Unlike many depression drugs, which need weeks to take effect … Continue reading “Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%”
As Alzheimer’s Conference Kicks Off, All Eyes Are on Biogen’s Drug
It’s the “era of neuroscience”; an industry “turning point”; and “an amazing time”—superlatives were flowing freely as the 12th annual Clinical Trials on Alzheimer’s Disease congress (CTAD) kicked off in rainy San Diego late Wednesday afternoon. The atmosphere felt thick with anticipation as attendees massed in the downtown hotel where the conference is taking place, … Continue reading “As Alzheimer’s Conference Kicks Off, All Eyes Are on Biogen’s Drug”
6 Experimental Alzheimer’s Disease Diagnostics Projects Get Funding Boost
Scientists gathered this week in San Diego at the annual Clinical Trials on Alzheimer’s Disease Congress are focused on ways to treat the neurodegenerative disease, a task that continues to vex those working to develop potential medicines. Others are working on an intimately related problem: early detection of the disease and related dementias. On Wednesday … Continue reading “6 Experimental Alzheimer’s Disease Diagnostics Projects Get Funding Boost”
Nektar Therapeutics Names John Northcott Chief Commercial Officer
John Northcott has joined Nektar Therapeutics (NASDAQ: [[ticker:NKTR]]) in the newly created role of senior vice president and chief commercial officer. Northcott was most recently the chief commercial officer of AbbVie (NYSE: [[ticker:ABBV]]) subsidiary Pharmacyclics. His experience also includes positions at Roche’s Genentech unit, Lexicon Pharmaceuticals (NASDAQ: [[ticker:LXRX]]), Merck (NYSE: [[ticker:MRK]]), and Pfizer (NYSE: [[ticker:PFE]]). … Continue reading “Nektar Therapeutics Names John Northcott Chief Commercial Officer”
Avrobio’s Gabriel Cohn Joins Homology as Chief Medical Officer
Homology Medicines (NASDAQ: [[ticker:FIXX]]) has appointed Gabriel Cohn to serve as its chief medical officer. Cohn was most recently vice president of clinical development at Avrobio (NASDAQ: [[ticker:AVRO]]). His experience also includes positions at Shire, Baystate Medical Center, and the Tufts University School of Medicine. Homology, which is developing gene-editing medicines and gene therapies, raised … Continue reading “Avrobio’s Gabriel Cohn Joins Homology as Chief Medical Officer”